Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Has announcements × vorasidenib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Carboplatin 17 pembrolizumab 13 Cisplatin 13 Rituximab 10 Gemcitabine 10 durvalumab 9 Pemetrexed 9 Paclitaxel 9 Nivolumab 9 Lenalidomide 6 Dexamethasone 6 osimertinib 5 olaparib 5 acalabrutinib 5 Prednisone 5 Cyclophosphamide 5 Capecitabine 5 Bortezomib 5 Bevacizumab 5 tremelimumab 4 niraparib 4 daratumumab 4 cabozantinib 4 amivantamab 4 abemaciclib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 Etoposide 4 Docetaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Servier

Phase 3 Active not recruiting

331 enrolled 25 charts 1 FDA

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡